Roche Venture Fund Portfolio

Our current portfolio includes more than 30 companies. We seek to add value to our companies and create highly valuable business enterprises.

Aligos

We discover targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH).

Bonum Therapeutics

Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.

Civi Biopharma

Focused on creating novel therapies against diseases where the unmet medical need exists.

Cour

COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease.

DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of diabetic patients around the world.

Enliven Therapeutics

We are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.

Enthera

First-in-class therapeutics for auto-immune disorders

Entrada

Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases

Forcefield Therapeutics

Revolutionising the treatment of heart attacks.

Freenome

Freenome is a biotechnology company based in South San Francisco that has pioneered the most comprehensive multiomics platform for early cancer detection with a simple blood test.

Glycoera

GlycoEra has developed a game-changing protein engineering and production platform to build a high-value pipeline of medicines.

Kumquat Biosciences

Developing innovative therapies to bring about sustainable and life-changing benefits to cancer patients.

Merge Therapeutics

Merge Therapeutics is developing first-in-class multispecific antibodies for a variety of immune-mediated diseases to our portfolio

Minoryx

Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high unmet medical need.

Mironid

Mironid® is developing novel small-molecule therapeutics that directly target the central signalling mechanism that drives ADPKD.

Mission Therapeutics

Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

NMD Pharma

NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases.

Noema Pharma

Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their lives to the fullest.

Sarepta Therapeutics

We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases

SpliceBio

SpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes.

Receptive Bio

Receptive Bio is advancing next-generation receptor-mediated shuttles to unlock therapeutic delivery to the brain and beyond

Tango Therapeutics

We are leveraging the principle of synthetic lethality to develop medicines that take direct aim at specific tumors.

Tempest Therapeutics

Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients.

Vivet Therapeutics

Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.

Discover more

Roche Venture FundRoche Venture Fund

We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.